We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+23.93%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$389M
AUM Growth
+$159M
Cap. Flow
+$127M
Cap. Flow %
32.66%
Top 10 Hldgs %
65.31%
Holding
60
New
19
Increased
8
Reduced
9
Closed
22

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$19.1M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$14.6M
3
AKAO
Achaogen Inc
AKAO
+$11M
4
KYNB
Kyntra Bio
KYNB
+$9.16M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$8.63M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$12.9M
2
PFE icon
Pfizer
PFE
+$11.8M
3
KITE
Kite Pharma, Inc.
KITE
+$10.4M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$9.78M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$7.83M

Sector Composition

Rank Sector Weight
1 Healthcare 50.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$130M 33.4%
+1,500,000
New +$120M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$20.3M 5.22%
+373,000
New +$19.1M
TEVA icon
3
PUT
Teva Pharmaceuticals
TEVA
$36.1B
$17.6M 4.53%
+1,000,000
New +$22.5M
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$15.2M 3.91%
+184,680
New +$14.6M
GSK icon
5
GSK
GSK
$100B
$14.5M 3.74%
286,442
+28,842
+11% +$1.46M
SGMO
6
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$11.7M 3.01%
+781,000
New +$8.63M
KYNB
7
Kyntra Bio
KYNB
$28.5M
$11.7M 3.01%
+8,693
New +$9.16M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.4B
$11.1M 2.86%
119,661
+18,861
+19% +$1.67M
IMMU
9
DELISTED
Immunomedics Inc
IMMU
$11.1M 2.85%
+792,106
New +$7.89M
ACRS icon
10
Aclaris Therapeutics
ACRS
$778M
$10.7M 2.76%
416,312
+76,312
+22% +$2.05M
SHPG
11
DELISTED
Shire pic
SHPG
$10.7M 2.74%
69,648
-31,852
-31% -$4.99M
DOVA
12
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$10.6M 2.74%
438,119
+240,060
+121% +$5.69M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$36.4B
$9.37M 2.41%
79,772
-25,228
-24% -$2.15M
AKAO
14
DELISTED
Achaogen Inc
AKAO
$9.21M 2.37%
+577,766
New +$11M
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
$8.74M 2.25%
62,337
-57,663
-48% -$7.83M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8.39M 2.16%
270,075
-70,025
-21% -$1.97M
IPXL
17
DELISTED
Impax Laboratories, Inc.
IPXL
$8.17M 2.1%
402,404
-157,996
-28% -$3.02M
ARRY
18
DELISTED
Array Biopharma Inc
ARRY
$7.57M 1.95%
+615,437
New +$5.72M
FLXN
19
DELISTED
Flexion Therapeutics, Inc.
FLXN
$6.56M 1.69%
271,136
+40,636
+18% +$955K
TSRO
20
PUT
DELISTED
TESARO, Inc.
TSRO
$6.46M 1.66%
50,000
– –
PRTK
21
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$6.08M 1.56%
242,300
+192,300
+385% +$4.48M
SUPN icon
22
Supernus Pharmaceuticals
SUPN
$2.75B
$5.29M 1.36%
+132,270
New +$5.72M
ABEO icon
23
CALL
Abeona Therapeutics
ABEO
$369M
$5.12M 1.32%
+12,000
New +$3.22M
CBIO
24
Crescent Biopharma
CBIO
$537M
$4.5M 1.16%
+3,213
New +$3.77M
INSM icon
25
Insmed
INSM
$23.2B
$4.49M 1.16%
144,000
-16,000
-10% -$305K
1
2 3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Nexthera Capital held 60 positions worth $389M, up 69% from $230M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Nexthera Capital deployed $127M of net new capital in Q3 2017, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 373,000 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 71% a quarter earlier.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $7.83M trimmed.

  • Nexthera Capital's largest Q3 2017 buy was Seagen Inc. Common Stock: 373,000 shares worth $20.3M.
  • Nexthera Capital added most to Dova Pharmaceuticals, Inc. Common Stock in Q3 2017, an estimated $5.69M increase.
  • Nexthera Capital's biggest Q3 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $7.83M.
  • Nexthera Capital fully exited Celgene Corp in Q3 2017, selling an estimated $12.9M.
  • Nexthera Capital's ten largest holdings make up 65% of its $389M portfolio in Q3 2017.
  • Nexthera Capital opened 19 new positions and closed 22 in Q3 2017.
  • Nexthera Capital's portfolio value rose 69% quarter-over-quarter to $389M.

Based on Nexthera Capital's 13F filing for Q3 2017, filed 14 Nov 2017.